[ad_1]
In 2014, Novartis spun off several corporate divisions. The animal health division was taken over by the subsidiary of the US pharmaceutical company Eli Lilly, Elanco.
Around 350 employees are spread over the two Swiss locations of Basel and Saint-Aubin in the canton of Friborg. This number will now be reduced by 94 positions, a company spokeswoman told “Schweiz aktuell”. The layoffs will take place in three phases from now until June 2021.
The reason for the reduction is the purchase of Bayer’s animal health division in August. Now they want to remove any duplication. Of the 3,000 employees worldwide, 900 jobs would be cut, but in Basel this would be higher than average. However, the group did not provide an explanation.
In Basel, research and development with 50 jobs, 27 jobs in production management and 17 in other functions are affected. Around 110 employees would remain in Basel after the decommissioning.
Unhappiness of the unions
Elanco’s restructuring plans do not necessarily meet goodwill. Especially since the company made headlines with layoffs before (Telebasel reported). Previous job cuts caused resentment as they delivered on promises to expand or secure locations.
As early as 2017, the Swiss Employees Union was upset that the layoffs were supposed to be very cautious. Even three years later, they want to do without media reporting. Only the information required by law was provided. The unions were not informed, SRF explains.
